New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
Gil-Sierra Manuel DavidMaria Del Pilar Briceño-CasadoMoreno-Ramos CristinaPublished in: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners (2023)
The efficacy of mobocertinib, amivantamab and poziotinib in NSCLC with EGFR exon 20 insertion mutations is promising. However, therapies were assessed in single-arm CTs with low-quality evidence. Comparative studies with more extensive patient follow-up, larger sample size and better design are needed to reliably quantify the effect of these drugs.